Cancer drug developer says cash lasts into late 2027 as key trial nears DENALI dose confirmation is due in 1H 2026, with topline data expected by year-end. Zentalis also plans to start its Phase 3 ASPENOVA trial in 1H.

#ZNTL Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Leading Indicators, Wednesday January 7, 2026 – Crystal Equity Research

Small-cap stocks in new uptrend according to average directional index, Wed Jan 7th - #QUIK #SDA #WLDN #ZNTL #AEVA #BACQ #DTI #ESQ #HYFT #ICHR #LUCD #NVAX #PGEN #SB #OGN #NSP #LPG #IHD #FC #EBS #CYD #BKSY - More: crystalequityresearch.com/leading-indi... - #smallcap

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress Zentalis (Nasdaq: ZNTL) reported third quarter 2025 results and operational updates on Nov 10, 2025. The company has $280.7 million in cash, cash equivalents and marketable securities, which it says provides runway into late 2027. The Phase 2 DENALI trial of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer remains on track with topline data from Part 2 expected by year-end 2026 and potential to support accelerated approval, subject to FDA feedback. Enrollment completed in the TETON Phase 2 uterine serous carcinoma trial; results are planned for publication in first half 2026. Quarterly operating expenses declined to $33.7M.

#ZNTL Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Zentalis (Nasdaq: ZNTL) announced four azenosertib poster presentations at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22–26, 2025 in Boston.Presentations include Phase 1 dose escalation/expansion results, Cyclin E1 biomarker findings supporting late‑stage development in Cyclin E1‑positive platinum‑resistant ovarian cancer (noted as ~50% of PROC), a trial‑in‑progress DENALI Part 2 biomarker study (GOG‑3066), and a trastuzumab deruxtecan + azenosertib combination study in HER2‑expressing tumors. Posters are scheduled October 23–24, 2025 and will be available via Zentalis' Publications page on the presentation days.

#ZNTL Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Zentalis (ZNTL) Q2 Loss Narrows 70% | The Motley Fool

#ZNTL #1506cafb-fdf9-4d90-8892-a959d3f2bc09 #data-news

Origin | Interest | Match

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported Q2 2025 financial results and provided updates on its clinical progress. The company's lead candidate azenosertib is advancing in the Phase 2 DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with topline data expected by year-end 2026.The company maintains a strong financial position with $303.4 million in cash and equivalents, providing runway into late 2027. Operating expenses decreased to $36.1 million from $65.1 million year-over-year, reflecting the company's strategic restructuring announced in January 2025. R&D expenses decreased to $27.6 million from $48.4 million in the prior year.

#ZNTL Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Leading Indicators, Monday July 28, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend with AROON Oscillator - #OBIO #PDFS #SPWH #TCBK #UPLD #WVE #ZNTL #ACCO #BORR #DEC #EAI #FF #KRP #PRO #QUAD #RIG #SES #NESR #MFIN #LGHL #KYTX #IMMP #FATE #EVAX #DAKT #BAND #AOB - More: crystalequityresearch.com/ieading-indi... - #smallcap

Zentalis Ovarian Cancer Drug Shows Promising 34.9% Response Rate in Latest Trial Data, Maintains Strong Financial Position Latest clinical data reveals 34.9% response rate in platinum-resistant ovarian cancer trial. First patient dosed in DENALI Part 2a study. See financial highlights.

#ZNTL Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Breakthrough: New Cancer Drug Achieves 35% Response Rate in Hard-to-Treat Ovarian Cancer Patients Latest trial data reveals promising efficacy for targeted therapy in platinum-resistant ovarian cancer. Discover how biomarker-driven approach impacts patient outcomes. See results.

#ZNTL Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates Zentalis Pharmaceuticals (NASDAQ: ZNTL) reported significant progress in 2024 with its lead drug candidate azenosertib. The company presented promising clinical data for treating Cyclin E1+ platinum-resistant ovarian cancer (PROC), showing a 34.9% objective response rate and 6.3-month median duration of response in the DENALI Part 1b study.Key developments include FDA Fast Track Designation for azenosertib and alignment on DENALI Part 2 study design, with topline data expected by year-end 2026. The company ended 2024 with $371.1 million in cash and equivalents, projecting runway into late 2027.Financial results show R&D expenses decreased to $167.8 million from $189.6 million in 2023, while G&A expenses increased to $87.1 million from $64.4 million. A strategic restructuring announced in January 2025 aims to support late-stage clinical development of azenosertib.

#ZNTL Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer Zentalis Pharmaceuticals (NASDAQ: ZNTL) has presented updated clinical data from Part 1b of the DENALI trial for azenosertib in platinum-resistant ovarian cancer (PROC) patients at the SGO 2025 Annual Meeting. The trial showed an objective response rate (ORR) of 34.9% in response-evaluable patients with Cyclin E1+ PROC tumors, and a median duration of response (mDOR) of 6.3 months.The Phase 2 single-arm study evaluated azenosertib monotherapy at 400mg QD 5:2 dose in 102 PROC patients. The data demonstrated Cyclin E1 protein overexpression as a predictive biomarker, with approximately 50% of PROC patients overexpressing Cyclin E1. Common treatment-related adverse events included gastrointestinal toxicities and fatigue.The company plans to initiate DENALI Part 2 in 1H 2025, with topline data expected by year-end 2026. If successful, the trial could support accelerated approval, subject to FDA review.

#ZNTL Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Can Zentalis's Azenosertib Change Treatment Landscape for Resistant Ovarian Cancer? Updated Phase 2 DENALI trial data highlights Cyclin E1 as potential predictive biomarker, plus synergistic effects with antibody drug conjugates.

#ZNTL Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Zentalis Pharmaceuticals' Investor Claims Under Investigation by Pomerantz Law Firm Pomerantz Law Firm is probing potential securities fraud and unlawful practices against Zentalis Pharmaceuticals. A significant stock price drop followed a major restructuring announcement.

Zentalis Pharmaceuticals' Investor Claims Under Investigation by Pomerantz Law Firm #United_States #New_York #Pomerantz_Law_Firm #Zentalis_Pharmaceuticals #ZNTL

Pomerantz Law Firm Investigates Zentalis Pharmaceuticals for Securities Fraud Claims Pomerantz Law Firm is investigating potential securities fraud claims involving Zentalis Pharmaceuticals. Investors may be affected.

Pomerantz Law Firm Investigates Zentalis Pharmaceuticals for Securities Fraud Claims #United_States #New_York #Pomerantz_LLP #Zentalis_Pharmaceuticals #ZNTL

Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 35% Success Rate Zentalis' azenosertib demonstrates promising 35% response rate in platinum-resistant ovarian cancer trial, with 5.5-month duration of response. FDA-aligned Phase 2 study planned for 2025.

#ZNTL Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Major Shakeup at Zentalis: Cancer Drug Developer Slashes Jobs to Double Down on Breakthrough Treatment Zentalis announces strategic restructuring with 40% workforce reduction, focusing resources on late-stage development of azenosertib. Cash runway extended to 2027 ahead of key trial data.

#ZNTL Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

www.stocktitan.net/news/ZNTL/zentalis-pharm...

Zentalis Pharmaceuticals Strengthens Leadership Team with Strategic Biotech Executive Appointments Zentalis bolsters executive roster with biotech veterans Wendy Chang and Haibo Wang, bringing M&A expertise and leadership experience from Merck, Gilead, and Amgen.

#ZNTL Zentalis Pharmaceuticals Announces Key Management Appointments

#stocks #StockMarket #investing

www.stocktitan.net/news/ZNTL/zentalis-pharm...

BREAKING NEWS: ( NASDAQ: #ZNTL ) Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

#StockMarket #News

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CLMT, #GME, #ZNTL, #UVIX, #VKTX

#OptionFlow #OptionsTrading #Trading

BREAKING NEWS: ( NASDAQ: #ZNTL ) Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) Near the Top of Equities by Percentage Gain on 9/16

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #ZNTL ) Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

#StockMarket #News